CTLA4 and melanoma: Immune checkpoint inhibitor (ICI)-based therapies, specifically anti-cytotoxic T lymphocyte-associated antigen-4 (anti-CTLA-4) and anti-programmed death-1 (anti-PD-1) antibodies, have transformed our understanding and management of melanoma in recent years.